A radiologist reading a chest CT scan today is rarely working alone. In an increasing share of U.S. hospitals, an AI triage layer has already reviewed the study before a human ever opens it — flagging a suspected pulmonary embolism, prioritizing it to the top of the reading queue, and drawing a bounding box around the region of concern. This is the quiet, largely invisible way artificial intelligence has entered clinical radiology: not as a replacement for the radiologist, but as a triage and second-read layer working underneath the existing workflow.
From Pattern Recognition to Clinical Triage
The FDA has now cleared more AI-based radiology tools than any other category of clinical AI software — well over 700 as of the most recent count, spanning stroke detection, fracture identification, pulmonary nodule characterization, and mammography density scoring. Most of these tools share a common architecture: a convolutional neural network trained on hundreds of thousands of labeled images learns to recognize the visual signature of a specific finding, then outputs a probability score and, often, a heat map showing where in the image it detected the pattern.
The clinical value isn't primarily diagnostic accuracy in isolation — it's triage speed. Stroke-detection AI from companies like Viz.ai and RapidAI can flag a large-vessel occlusion on a CT angiogram and alert the on-call neurointerventional team before the radiologist has finished dictating the report, shaving critical minutes off door-to-treatment time in a condition where "time is brain."
Where AI Outperforms — and Where It Doesn't
Multiple prospective studies have now shown AI-assisted mammography readers catching subtle cancers that a single human reader missed, particularly in dense breast tissue where masses can hide against similarly bright background parenchyma. A 2023 study published in The Lancet Oncology tracking over 80,000 women found AI-supported screening detected 20% more cancers than standard double-reading by two radiologists, while reducing radiologist workload by roughly 44%.
But AI performance drops sharply outside its training distribution. A model trained predominantly on images from one manufacturer's CT scanner, one patient population, and one disease prevalence rate can underperform significantly when deployed at a different facility with different equipment and demographics — a phenomenon researchers call "distribution shift." This is why the FDA increasingly requires post-market performance monitoring as a condition of clearance, and why radiology groups are learning to treat AI output as one input among several rather than a verdict.
The Workflow Reality: Second Reader, Not First Reader
In nearly every U.S. deployment, AI functions as a concurrent or second reader rather than an autonomous first read. The radiologist still interprets the study; the AI output appears alongside as a prompt, a priority flag, or a quantitative measurement (like automated aortic diameter tracking for aneurysm surveillance). The one meaningful exception is diabetic retinopathy screening, where the FDA has cleared fully autonomous AI systems that can render a screening result without a physician in the loop — a narrow, well-defined use case with a binary yes/no clinical action (refer or don't refer).
Liability and the Standard of Care Question
An unresolved legal question looms over the entire field: if a radiologist overrides an AI flag and the AI was right, who bears liability? Conversely, if a radiologist defers to an AI recommendation that turns out wrong, does that count as appropriate reliance on cleared clinical decision support, or a failure to independently verify? Most malpractice carriers currently treat AI output the same as any other diagnostic aid — the radiologist remains the responsible clinical decision-maker, and documentation of independent clinical judgment matters as much as it did before AI entered the room.
What This Means for Facility Purchasing
For imaging centers and hospital radiology departments, the practical purchasing decision increasingly involves evaluating not just image acquisition hardware but the AI software layer that will read alongside it — including ongoing subscription costs, integration with existing PACS systems, and the vendor's post-market monitoring track record. Facilities equipping or expanding imaging suites can source diagnostic equipment from our catalog to support both acquisition and downstream reading workflows.
Conclusion
AI in radiology has moved past the hype cycle into routine, if uneven, clinical deployment. The technology is genuinely improving triage speed and catching findings human readers occasionally miss — but it is augmenting the radiologist's judgment, not replacing it, and the facilities getting the most value are the ones that have built clear protocols for when to trust the flag and when to look again.
